| 3.645 -0.235 (-6.06%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.75  |
1-year : | 6.8 |
| Resists | First : | 4.92 |
Second : | 5.82 |
| Pivot price | 4.34 |
|||
| Supports | First : | 3.46 |
Second : | 2.87 |
| MAs | MA(5) : | 3.93 |
MA(20) : | 4.53 |
| MA(100) : | 2.93  |
MA(250) : | 2.02 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 16.5 |
D(3) : | 16.9 |
| RSI | RSI(14): 37.6 |
|||
| 52-week | High : | 5.88 | Low : | 0.36 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ELEV ] has closed above bottom band by 5.8%. Bollinger Bands are 19.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.92 - 3.95 | 3.95 - 3.97 |
| Low: | 3.41 - 3.44 | 3.44 - 3.46 |
| Close: | 3.61 - 3.65 | 3.65 - 3.68 |
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Wed, 24 Apr 2024
Elevation Oncology Announces Pricing of $50 Million Public Offering - The Globe and Mail
Wed, 24 Apr 2024
Steve Cohen's Point72 Disclosed 8.7% Stake In Elevation Oncology - The Globe and Mail
Mon, 22 Apr 2024
Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade) (NASDAQ:ELEV) - Seeking Alpha
Wed, 17 Apr 2024
Short Interest in Elevation Oncology, Inc. (NASDAQ:ELEV) Rises By 8.2% - MarketBeat
Mon, 08 Apr 2024
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 - PR Newswire
Mon, 11 Mar 2024
Does Elevation Oncology Inc (ELEV) Have What it Takes to be in Your Portfolio Monday? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 86.4 (%) |
| Shares Short | 5,010 (K) |
| Shares Short P.Month | 3,610 (K) |
| EPS | -1.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.6 % |
| Return on Equity (ttm) | -88.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -2.73 |
| PEG Ratio | 0 |
| Price to Book value | 2.82 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|